To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
A pharma industry veteran with over three decades of experience in domestic as well as international markets
He is a Chartered Accountant with more than 19 years of extensive experience
Subscribe To Our Newsletter & Stay Updated
